Vasculitis & polymyalgia rheumatica
Serum CXCL6 as a biomarker for diagnosing and predicting progression of interstitial lung disease in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis
Authors' conclusion
This exploratory study suggests that elevated serum CXCL6 levels are associated with greater frequency and disease progression of ILD in AAV patients.
Study context
- Population
- Patients with AAV and healthy controls292 AAV, 82 healthy controls
- Comparison
- High vs low baseline serum CXCL6 levels in AAV
- Outcome
- Serum CXCL6 as a biomarker at diagnosis and predictor of ILD progression in AAV
Methodological detailsexploratory, univariable and multivariable analyses
- Exploratory
- Univariable and multivariable analyses
Main finding
As reported in the abstract
Frequency of ILD in AAV patients
P = 0.002
Further findings
ILD progression during follow-up among AAV-ILD patients
P = 0.023
Interstitial lung disease (ILD) progression during follow-up among AAV-ILD patients
- High baseline CXCL6 independently associated with ILD progression in multivariate regression
Correlation of baseline CXCL6 with disease activity and acute-phase reactants
- Positive correlation with AAV disease activity, ESR and CRP
Original publication
Serum CXCL6 as a biomarker for diagnosing and predicting progression of interstitial lung disease in ANCA-associated vasculitis. Arthritis Res Ther. Published 28 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →